Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 763

1.

High-Risk Cardiovascular Conditions in Sports-Related Sudden Death: Prevalence in 5,169 Schoolchildren Screened via Cardiac Magnetic Resonance.

Angelini P, Cheong BY, Lenge De Rosen VV, Lopez A, Uribe C, Masso AH, Ali SW, Davis BR, Muthupillai R, Willerson JT.

Tex Heart Inst J. 2018 Aug 1;45(4):205-213. doi: 10.14503/THIJ-18-6645. eCollection 2018 Aug.

2.

Racial Disparities in CD34+ Cells and Their Influence on Cardiovascular Repair.

Taylor DA, Willerson JT.

Circ Res. 2018 Aug 3;123(4):401-403. doi: 10.1161/CIRCRESAHA.118.313546. No abstract available.

PMID:
30355257
3.

A New High-Performance Gadonanotube-Polymer Hybrid Material for Stem Cell Labeling and Tracking by MRI.

Moghaddam SE, Hernández-Rivera M, Zaibaq NG, Ajala A, da Graça Cabreira-Hansen M, Mowlazadeh-Haghighi S, Willerson JT, Perin EC, Muthupillai R, Wilson LJ.

Contrast Media Mol Imaging. 2018 Jul 10;2018:2853736. doi: 10.1155/2018/2853736. eCollection 2018.

4.

Rationale and Design of the SENECA (StEm cell iNjECtion in cAncer survivors) Trial.

Bolli R, Hare JM, Henry TD, Lenneman CG, March KL, Miller K, Pepine CJ, Perin EC, Traverse JH, Willerson JT, Yang PC, Gee AP, Lima JA, Moyé L, Vojvodic RW, Sayre SL, Bettencourt J, Cohen M, Ebert RF, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN).

Am Heart J. 2018 Jul;201:54-62. doi: 10.1016/j.ahj.2018.02.009. Epub 2018 Apr 4.

PMID:
29910056
5.

Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit+ Cardiac Stem Cells As Regenerative Therapy for Heart Failure).

Bolli R, Hare JM, March KL, Pepine CJ, Willerson JT, Perin EC, Yang PC, Henry TD, Traverse JH, Mitrani RD, Khan A, Hernandez-Schulman I, Taylor DA, DiFede DL, Lima JAC, Chugh A, Loughran J, Vojvodic RW, Sayre SL, Bettencourt J, Cohen M, Moyé L, Ebert RF, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN).

Circ Res. 2018 Jun 8;122(12):1703-1715. doi: 10.1161/CIRCRESAHA.118.312978. Epub 2018 Apr 27.

PMID:
29703749
6.

Hypertrophy Regression With N-Acetylcysteine in Hypertrophic Cardiomyopathy (HALT-HCM): A Randomized, Placebo-Controlled, Double-Blind Pilot Study.

Marian AJ, Tan Y, Li L, Chang J, Syrris P, Hessabi M, Rahbar MH, Willerson JT, Cheong BY, Liu CY, Kleiman NS, Bluemke DA, Nagueh SF.

Circ Res. 2018 Apr 13;122(8):1109-1118. doi: 10.1161/CIRCRESAHA.117.312647. Epub 2018 Mar 14.

PMID:
29540445
7.

Magnetic Resonance Imaging of Atherosclerotic Plaque at Clinically Relevant Field Strengths (1T) by Targeting the Integrin α4β1.

Woodside DG, Tanifum EA, Ghaghada KB, Biediger RJ, Caivano AR, Starosolski ZA, Khounlo S, Bhayana S, Abbasi S, Craft JW Jr, Maxwell DS, Patel C, Stupin IV, Bakthavatsalam D, Market RV, Willerson JT, Dixon RAF, Vanderslice P, Annapragada AV.

Sci Rep. 2018 Feb 27;8(1):3733. doi: 10.1038/s41598-018-21893-x.

8.

Magnetic Resonance Imaging-Based Screening Study in a General Population of Adolescents.

Angelini P, Cheong BY, Lenge De Rosen VV, Lopez JA, Uribe C, Masso AH, Ali SW, Davis BR, Muthupillai R, Willerson JT.

J Am Coll Cardiol. 2018 Feb 6;71(5):579-580. doi: 10.1016/j.jacc.2017.11.051. No abstract available.

PMID:
29406865
9.

Global Overview of the Transnational Alliance for Regenerative Therapies in Cardiovascular Syndromes (TACTICS) Recommendations: A Comprehensive Series of Challenges and Priorities of Cardiovascular Regenerative Medicine.

Fernández-Avilés F, Sanz-Ruiz R, Climent AM, Badimon L, Bolli R, Charron D, Fuster V, Janssens S, Kastrup J, Kim HS, Lüscher TF, Martin JF, Menasché P, Pinto FJ, Simari RD, Stone GW, Terzic A, Willerson JT, Wu JC; TACTICS Writing Group.

Circ Res. 2018 Jan 19;122(2):199-201. doi: 10.1161/CIRCRESAHA.117.312099. No abstract available.

PMID:
29348246
10.

Suppression of Activated FOXO Transcription Factors in the Heart Prolongs Survival in a Mouse Model of Laminopathies.

Auguste G, Gurha P, Lombardi R, Coarfa C, Willerson JT, Marian AJ.

Circ Res. 2018 Mar 2;122(5):678-692. doi: 10.1161/CIRCRESAHA.117.312052. Epub 2018 Jan 9.

PMID:
29317431
11.

TIME Trial: Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function: Final 2-Year Analysis.

Traverse JH, Henry TD, Pepine CJ, Willerson JT, Chugh A, Yang PC, Zhao DXM, Ellis SG, Forder JR, Perin EC, Penn MS, Hatzopoulos AK, Chambers JC, Baran KW, Raveendran G, Gee AP, Taylor DA, Moyé L, Ebert RF, Simari RD.

Circ Res. 2018 Feb 2;122(3):479-488. doi: 10.1161/CIRCRESAHA.117.311466. Epub 2017 Dec 5.

PMID:
29208679
12.
13.

Distinct Cellular Basis for Early Cardiac Arrhythmias, the Cardinal Manifestation of Arrhythmogenic Cardiomyopathy, and the Skin Phenotype of Cardiocutaneous Syndromes.

Karmouch J, Zhou QQ, Miyake CY, Lombardi R, Kretzschmar K, Bannier-Hélaouët M, Clevers H, Wehrens XHT, Willerson JT, Marian AJ.

Circ Res. 2017 Dec 8;121(12):1346-1359. doi: 10.1161/CIRCRESAHA.117.311876. Epub 2017 Oct 10.

14.

Hippo pathway deficiency reverses systolic heart failure after infarction.

Leach JP, Heallen T, Zhang M, Rahmani M, Morikawa Y, Hill MC, Segura A, Willerson JT, Martin JF.

Nature. 2017 Oct 12;550(7675):260-264. doi: 10.1038/nature24045. Epub 2017 Oct 4.

15.

Direct Stimulation of Cardiogenesis: A New Paradigm for Treating Heart Disease.

Martin JF, Perin EC, Willerson JT.

Circ Res. 2017 Jun 23;121(1):13-15. doi: 10.1161/CIRCRESAHA.117.311062. No abstract available.

16.

Global position paper on cardiovascular regenerative medicine.

Fernández-Avilés F, Sanz-Ruiz R, Climent AM, Badimon L, Bolli R, Charron D, Fuster V, Janssens S, Kastrup J, Kim HS, Lüscher TF, Martin JF, Menasché P, Simari RD, Stone GW, Terzic A, Willerson JT, Wu JC; TACTICS (Transnational Alliance for Regenerative Therapies in Cardiovascular Syndromes) Writing Group; Authors/Task Force Members. Chairpersons; Basic Research Subcommittee; Translational Research Subcommittee; Challenges of Cardiovascular Regenerative Medicine Subcommittee; Tissue Engineering Subcommittee; Delivery, Navigation, Tracking and Assessment Subcommittee; Clinical Trials Subcommittee; Regulatory and funding strategies subcommittee; Delivery, Navigation, Tracking and Assessment Subcommittee.

Eur Heart J. 2017 Sep 1;38(33):2532-2546. doi: 10.1093/eurheartj/ehx248. No abstract available.

17.

The Texas Heart Institute: Part 2-Working Toward the Next Breakthrough in Cardiovascular Medicine.

Willerson JT.

Circ Res. 2017 May 12;120(10):1548-1550. doi: 10.1161/CIRCRESAHA.117.311130. No abstract available.

PMID:
28495990
18.

The Texas Heart Institute: Part 1-An Historical Perspective.

Willerson JT.

Circ Res. 2017 May 12;120(10):1545-1547. doi: 10.1161/CIRCRESAHA.117.310760. No abstract available.

PMID:
28495989
19.

The ubiquitin-proteasome system: A potential therapeutic target for heart failure.

Barac YD, Emrich F, Krutzwakd-Josefson E, Schrepfer S, Sampaio LC, Willerson JT, Robbins RC, Ciechanover A, Mohr FW, Aravot D, Taylor DA.

J Heart Lung Transplant. 2017 Jul;36(7):708-714. doi: 10.1016/j.healun.2017.02.012. Epub 2017 Feb 20. Review.

PMID:
28341100
20.

Fare Thee Well, Dr. Cooley.

Fred HL, Willerson JT.

Tex Heart Inst J. 2017 Feb 1;44(1):3-6. doi: 10.14503/THIJ-17-6232. eCollection 2017 Feb. No abstract available.

21.

A Potential Oligogenic Etiology of Hypertrophic Cardiomyopathy: A Classic Single-Gene Disorder.

Li L, Bainbridge MN, Tan Y, Willerson JT, Marian AJ.

Circ Res. 2017 Mar 31;120(7):1084-1090. doi: 10.1161/CIRCRESAHA.116.310559. Epub 2017 Feb 21.

22.

CD133+ Stem Cells in the Treatment of Patients With Refractory Angina.

Willerson JT.

Circ Res. 2017 Feb 17;120(4):602-603. doi: 10.1161/CIRCRESAHA.117.310445. No abstract available.

PMID:
28209787
23.

Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN PACE Trial (Patients With Intermittent Claudication Injected With ALDH Bright Cells).

Perin EC, Murphy MP, March KL, Bolli R, Loughran J, Yang PC, Leeper NJ, Dalman RL, Alexander J, Henry TD, Traverse JH, Pepine CJ, Anderson RD, Berceli S, Willerson JT, Muthupillai R, Gahremanpour A, Raveendran G, Velasquez O, Hare JM, Hernandez Schulman I, Kasi VS, Hiatt WR, Ambale-Venkatesh B, Lima JA, Taylor DA, Resende M, Gee AP, Durett AG, Bloom J, Richman S, G'Sell P, Williams S, Khan F, Gyang Ross E, Santoso MR, Goldman J, Leach D, Handberg E, Cheong B, Piece N, DiFede D, Bruhn-Ding B, Caldwell E, Bettencourt J, Lai D, Piller L, Simpson L, Cohen M, Sayre SL, Vojvodic RW, Moyé L, Ebert RF, Simari RD, Hirsch AT; Cardiovascular Cell Therapy Research Network (CCTRN).

Circulation. 2017 Apr 11;135(15):1417-1428. doi: 10.1161/CIRCULATIONAHA.116.025707. Epub 2017 Feb 16.

24.

Denton Arthur Cooley, MD.

Willerson JT.

Circ Res. 2017 Jan 6;120(1):17-19. doi: 10.1161/CIRCRESAHA.116.310451. No abstract available.

PMID:
28057783
25.

Identification of cardiovascular risk factors associated with bone marrow cell subsets in patients with STEMI: a biorepository evaluation from the CCTRN TIME and LateTIME clinical trials.

Contreras A, Orozco AF, Resende M, Schutt RC, Traverse JH, Henry TD, Lai D, Cooke JP, Bolli R, Cohen ML, Moyé L, Pepine CJ, Yang PC, Perin EC, Willerson JT, Taylor DA; Cardiovascular Cell Therapy Research Network (CCTRN).

Basic Res Cardiol. 2017 Jan;112(1):3. Epub 2016 Nov 23.

26.

Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial.

Bhatnagar A, Bolli R, Johnstone BH, Traverse JH, Henry TD, Pepine CJ, Willerson JT, Perin EC, Ellis SG, Zhao DX, Yang PC, Cooke JP, Schutt RC, Trachtenberg BH, Orozco A, Resende M, Ebert RF, Sayre SL, Simari RD, Moyé L, Cogle CR, Taylor DA; Cardiovascular Cell Therapy Research Network (CCTRN).

Am Heart J. 2016 Sep;179:142-50. doi: 10.1016/j.ahj.2016.06.018. Epub 2016 Jul 6.

27.

Knockdown of Plakophilin 2 Downregulates miR-184 Through CpG Hypermethylation and Suppression of the E2F1 Pathway and Leads to Enhanced Adipogenesis In Vitro.

Gurha P, Chen X, Lombardi R, Willerson JT, Marian AJ.

Circ Res. 2016 Sep 2;119(6):731-50. doi: 10.1161/CIRCRESAHA.116.308422. Epub 2016 Jul 28.

28.

Treatment of hind limb ischemia using angiogenic peptide nanofibers.

Kumar VA, Liu Q, Wickremasinghe NC, Shi S, Cornwright TT, Deng Y, Azares A, Moore AN, Acevedo-Jake AM, Agudo NR, Pan S, Woodside DG, Vanderslice P, Willerson JT, Dixon RA, Hartgerink JD.

Biomaterials. 2016 Aug;98:113-9. doi: 10.1016/j.biomaterials.2016.04.032. Epub 2016 Apr 26.

29.

The Athena trials: Autologous adipose-derived regenerative cells for refractory chronic myocardial ischemia with left ventricular dysfunction.

Henry TD, Pepine CJ, Lambert CR, Traverse JH, Schatz R, Costa M, Povsic TJ, David Anderson R, Willerson JT, Kesten S, Perin EC.

Catheter Cardiovasc Interv. 2017 Feb 1;89(2):169-177. doi: 10.1002/ccd.26601. Epub 2016 Sep 23.

PMID:
27148802
30.

Cardiac Fibro-Adipocyte Progenitors Express Desmosome Proteins and Preferentially Differentiate to Adipocytes Upon Deletion of the Desmoplakin Gene.

Lombardi R, Chen SN, Ruggiero A, Gurha P, Czernuszewicz GZ, Willerson JT, Marian AJ.

Circ Res. 2016 Jun 24;119(1):41-54. doi: 10.1161/CIRCRESAHA.115.308136. Epub 2016 Apr 27.

31.

Prostacyclin-producing human mesenchymal cells target H19 lncRNA to augment endogenous progenitor function in hindlimb ischaemia.

Deng Y, Yang Z, Terry T, Pan S, Woodside DG, Wang J, Ruan K, Willerson JT, Dixon RA, Liu Q.

Nat Commun. 2016 Apr 15;7:11276. doi: 10.1038/ncomms11276.

32.

Focus on ECGs: A New Feature of the Texas Heart Institute Journal.

Willerson JT.

Tex Heart Inst J. 2016 Feb 1;43(1):1. doi: 10.14503/THIJ-16-5747. eCollection 2016 Feb. No abstract available.

33.

In Memoriam: Kanu Chatterjee, MD (1934–2015).

Willerson JT.

Tex Heart Inst J. 2015 Aug;42(4):303-4. No abstract available.

34.

Cardiopulmonary Resuscitation for Out-of-Hospital Cardiac Arrest and the New Policy for Involving Schoolchildren.

Angelini P, Willerson JT.

Tex Heart Inst J. 2015 Dec 1;42(6):508-9. doi: 10.14503/THIJ-15-5467. eCollection 2015 Dec. No abstract available.

35.

Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN Trial.

Taylor DA, Perin EC, Willerson JT, Zierold C, Resende M, Carlson M, Nestor B, Wise E, Orozco A, Pepine CJ, Henry TD, Ellis SG, Zhao DX, Traverse JH, Cooke JP, Schutt RC, Bhatnagar A, Grant MB, Lai D, Johnstone BH, Sayre SL, Moyé L, Ebert RF, Bolli R, Simari RD, Cogle CR; Cardiovascular Cell Therapy Research Network (CCTRN).

Cell Transplant. 2016;25(9):1675-1687. Epub 2015 Nov 19.

36.

In memoriam: Ali Massumi, MD (1945-2015).

Willerson JT, Cooley DA, Rasekh A, Hall RJ.

Tex Heart Inst J. 2015 Jun;42(3):191-2. doi: 10.14503/THIJ-15-5296. No abstract available.

37.

Origin of the right coronary artery from the opposite sinus of Valsalva in adults: characterization by intravascular ultrasonography at baseline and after stent angioplasty.

Angelini P, Uribe C, Monge J, Tobis JM, Elayda MA, Willerson JT.

Catheter Cardiovasc Interv. 2015 Aug;86(2):199-208. doi: 10.1002/ccd.26069. Epub 2015 Jul 14.

38.

A Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells in Patients With Ischemic or Nonischemic Heart Failure.

Perin EC, Borow KM, Silva GV, DeMaria AN, Marroquin OC, Huang PP, Traverse JH, Krum H, Skerrett D, Zheng Y, Willerson JT, Itescu S, Henry TD.

Circ Res. 2015 Aug 28;117(6):576-84. doi: 10.1161/CIRCRESAHA.115.306332. Epub 2015 Jul 6.

PMID:
26148930
39.

Surfactant-free Gd(3+)-ion-containing carbon nanotube MRI contrast agents for stem cell labeling.

Gizzatov A, Hernández-Rivera M, Keshishian V, Mackeyev Y, Law JJ, Guven A, Sethi R, Qu F, Muthupillai R, Cabreira-Hansen Mda G, Willerson JT, Perin EC, Ma Q, Bryant RG, Wilson LJ.

Nanoscale. 2015 Jul 28;7(28):12085-91. doi: 10.1039/c5nr02078f. Epub 2015 Jun 29.

PMID:
26119138
40.

In memoriam: Joseph K. Perloff (1924–2014).

Willerson JT.

Tex Heart Inst J. 2015 Apr;42(2):103-4. No abstract available.

41.

Changing of the guard?

Willerson JT, Cabreira-Hansen MG, Taylor DA, Perin EC.

Eur Heart J. 2015 Jul 14;36(27):1711-3. doi: 10.1093/eurheartj/ehv219. Epub 2015 May 28. No abstract available.

PMID:
26022009
42.

Acellular human heart matrix: A critical step toward whole heart grafts.

Sánchez PL, Fernández-Santos ME, Costanza S, Climent AM, Moscoso I, Gonzalez-Nicolas MA, Sanz-Ruiz R, Rodríguez H, Kren SM, Garrido G, Escalante JL, Bermejo J, Elizaga J, Menarguez J, Yotti R, Pérez del Villar C, Espinosa MA, Guillem MS, Willerson JT, Bernad A, Matesanz R, Taylor DA, Fernández-Avilés F.

Biomaterials. 2015 Aug;61:279-89. doi: 10.1016/j.biomaterials.2015.04.056. Epub 2015 May 13.

PMID:
26005766
43.

Actin cytoskeletal remodeling with protrusion formation is essential for heart regeneration in Hippo-deficient mice.

Morikawa Y, Zhang M, Heallen T, Leach J, Tao G, Xiao Y, Bai Y, Li W, Willerson JT, Martin JF.

Sci Signal. 2015 May 5;8(375):ra41. doi: 10.1126/scisignal.2005781.

44.

Stem cell therapy for cardiovascular diseases: a progressive journey.

Willerson JT.

Curr Opin Cardiol. 2015 May;30(3):205-12. doi: 10.1097/HCO.0000000000000156. Review.

PMID:
25695897
45.

Recent developments in cardiovascular stem cells.

Madonna R, Ferdinandy P, De Caterina R, Willerson JT, Marian AJ.

Circ Res. 2014 Dec 5;115(12):e71-8. doi: 10.1161/CIRCRESAHA.114.305567. Review. No abstract available.

PMID:
25477490
46.

Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial.

Schutt RC, Trachtenberg BH, Cooke JP, Traverse JH, Henry TD, Pepine CJ, Willerson JT, Perin EC, Ellis SG, Zhao DX, Bhatnagar A, Johnstone BH, Lai D, Resende M, Ebert RF, Wu JC, Sayre SL, Orozco A, Zierold C, Simari RD, Moyé L, Cogle CR, Taylor DA; Cardiovascular Cell Therapy Research Network (CCTRN).

Circ Res. 2015 Jan 2;116(1):99-107. doi: 10.1161/CIRCRESAHA.116.304710. Epub 2014 Nov 18.

47.

Till truth makes all things plain: human hearts and stem cells.

Willerson JT, Taylor D, Perin EC.

Circ Res. 2014 Nov 7;115(11):908-10. doi: 10.1161/CIRCRESAHA.114.305340. No abstract available.

PMID:
25378531
48.

Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes.

Cogle CR, Wise E, Meacham AM, Zierold C, Traverse JH, Henry TD, Perin EC, Willerson JT, Ellis SG, Carlson M, Zhao DX, Bolli R, Cooke JP, Anwaruddin S, Bhatnagar A, da Graca Cabreira-Hansen M, Grant MB, Lai D, Moyé L, Ebert RF, Olson RE, Sayre SL, Schulman IH, Bosse RC, Scott EW, Simari RD, Pepine CJ, Taylor DA; Cardiovascular Cell Therapy Research Network (CCTRN).

Circ Res. 2014 Oct 24;115(10):867-74. doi: 10.1161/CIRCRESAHA.115.304353. Epub 2014 Aug 18.

49.

Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: The PRECISE Trial.

Perin EC, Sanz-Ruiz R, Sánchez PL, Lasso J, Pérez-Cano R, Alonso-Farto JC, Pérez-David E, Fernández-Santos ME, Serruys PW, Duckers HJ, Kastrup J, Chamuleau S, Zheng Y, Silva GV, Willerson JT, Fernández-Avilés F.

Am Heart J. 2014 Jul;168(1):88-95.e2. doi: 10.1016/j.ahj.2014.03.022. Epub 2014 Apr 5.

PMID:
24952864
50.

In memoriam: Mavis P. Kelsey, Sr. (1912-2013).

Cooley DA, Willerson JT.

Tex Heart Inst J. 2014 Apr;41(2):121-2. No abstract available.

Supplemental Content

Loading ...
Support Center